Laddar...
Early Treatment of High Risk Chronic Lymphocytic Leukemia with Alemtuzumab and Rituximab
BACKGROUND: CLL patients are usually only treated for progressive disease. However, the discovery of biological predictors of high risk of disease progression together with the development of newer more targeted therapies could change this paradigm. In this phase 2 study we tested the safety and eff...
Sparad:
| Huvudupphovsmän: | , , , , , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
2008
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2849723/ https://ncbi.nlm.nih.gov/pubmed/18759253 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.23824 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|